Company Profile
Replimune Group Stock Price, News & Analysis
- Ticker:
- REPL
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Replimune Group is followed within the biotech universe for its exposure to catalyst-driven execution.
Stock performance
11.42 USD (+2.15%)
Close
Last updated: June 23, 2026 at 00:00
942.98M USD
Market cap
Why the stock is moving
REPL is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Replimune Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Replimune Group is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Replimune Group follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Replimune Group sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
Source: Replimune Group
- 04
Replimune Provides Update Following Type A Meeting with FDA
Source: Replimune Group
- 05
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
Source: Replimune Group
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Replimune Group (REPL)?
Replimune Group (REPL) most recently closed at 11.42 USD, a +2.15% move versus the previous session.
What is the market cap of Replimune Group (REPL)?
Replimune Group currently has a market capitalization of 942.98M USD on BioPharmSignal.
What does Replimune Group do?
Replimune Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
On which exchange is REPL stock listed?
Replimune Group (REPL) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Replimune Group is followed within the biotech universe for its exposure to catalyst-driven execution., Biotechnology.
What is Replimune?
Replimune Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.
Which conditions is Replimune Group targeting with Replimune?
Replimune Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
What is Group?
Replimune Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.
What is Investors?
Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.